December 05, 2019

FDA Issues Warning Letters to 15 CBD Companies

The FDA issued 15 warning letters to CBD companies on November 25, citing them for marketing CBD products as a means to treat disease or as having certain therapeutic uses. The FDA noted that it has only approved one CBD drug product, Epidiolex. All other CBD products which are marketed as therapeutic or as providing treatment for disease will receive scrutiny as potentially violating the Food, Drug, and Cosmetic Act. The FDA plans to provide a progress update on its position on CBD in the coming weeks.